Company Overview: VRTX

Upcoming Projects (VRTX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (VRTX)

A 4th View: Examining the current treatment landscape for Alpha-1 Antitrypsin Deficiency including ALN-AAT02 from Alnylam and VX-814 from Vertex
Tickers: ALNY, VRTX, IONS
Executed On: Oct 24, 2019 at 01:00 PM EDT
A 3rd Look: A view on the current treatment landscape for Alpha-1 Antitrypsin Deficiency including ALN-AAT02 from Alnylam and VX-814 from Vertex
Tickers: ALNY, VRTX, IONS
Executed On: Oct 18, 2019 at 01:00 PM EDT
A 2nd Look: Examining the current treatment landscape for Alpha-1 Antitrypsin Deficiency including ALN-AAT02 from Alnylam and VX-814 from Vertex
Tickers: ALNY, VRTX, IONS
Executed On: Sep 20, 2019 at 12:00 PM EDT
A view on the current treatment landscape for Alpha-1 Antitrypsin Deficiency including ALN-AAT02 from Alnylam and VX-814 from Vertex
Tickers: ALNY, VRTX, IONS
Executed On: Sep 12, 2019 at 01:00 PM EDT
Understanding the current treatment paradigm in Cystic Fibrosis including Kalydeco, Orkambi, Symdeko & impact from the upcoming triple regimen
Ticker: VRTX
Executed On: Jul 16, 2018 at 10:00 AM EDT
Examining Proteostasis’ recent data in Cystic Fibrosis and how it compares to Vertex
Tickers: PTI, VRTX
Executed On: Feb 09, 2018 at 11:00 AM EST
Exploring the potential of ProQR Therapeutics' (PRQR) Cystic Fibrosis drug QR-010 after its Proof-Of-Concept Trial
Tickers: PRQR, VRTX, GLPG
Executed On: Jul 31, 2017 at 10:00 AM EDT
Another Opinion: Evaluating the strength of Concert Pharmaceutical`s broad patent estate covering deuterated compounds.
Tickers: CNCE, VRTX, JNJ, INCY, GLPG, ABBV
Executed On: May 04, 2017 at 11:00 AM EDT
Evaluating the strength of Concert Pharmaceutical`s broad patent estate covering deuterated compounds.
Tickers: CNCE, ABBV, INCY, VRTX, GLPG, JNJ
Executed On: May 02, 2017 at 12:00 PM EDT
Fridays with Adam Feuerstein #1
Tickers: JAZZ, SAGE, CELG, GLPG, VRTX
Executed On: Feb 17, 2017 at 02:00 PM EST
What are the chances that VRTX's ORKAMBI gets FDA approval for an expanded label for patients age 6-11 with homozygous F508del mutation Cystic Fibrosis?
Tickers: VRTX, GLPG, GILD
Executed On: Sep 21, 2016 at 12:30 PM EDT
Included with Membership

Upcoming & Overdue Catalysts (VRTX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (VRTX)

Based on Phase 3 trial results, Vertex Pharmaceuticals expects to submit an NDA for ORKAMBI as a treatment for cystic fibrosis in patients aged 2-5 with two copies of the F508del mutation in their CFTR gene, in Q1 2018
Ticker: VRTX
Occurred on: Apr 26, 2018
Vertex's Tezacaftor (VX-661) / ivacaftor in treating Cystic fibrosis - Two Copies of the F508del Mutation PDUFA date under priority review February 28, 2018
Ticker: VRTX
Occurred on: Feb 12, 2018
PDUFA date for Vertex Pharmaceutical's Tezacaftor, in combination with ivacaftor as a treatment for cystic fibrosis in paitents 12 years of age and older who have certain genetic markers, is set for February 28, 2018
Ticker: VRTX
Occurred on: Feb 12, 2018
Vertex plans to submit a New Drug Application (NDA) to the FDA for VX-661 in combination with ivacaftor in the second half of 2017
Ticker: VRTX
Occurred on: Aug 24, 2017
Vertex (VRTX) Expects Top-Line Phase 2 Data Evaluating Triple Combination Dosing With VX-152 in ~35 CF Patients With One F508del Mutation and One Minimal Function Mutation and ~25 CF Patients with Two Copies of F508del in H2 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
Phase I safety data on VX-152 / VX-440 expected in second half of 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
VX-152, VX-440 "triplet" potential Phase II efficacy data in hetero CF expected in early 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
Vertex (VRTX) Expects Top-Line Phase 2 Data Evaluating VX-440/Tezacaftor/Kalydeco in ~40 CF Patients With F508del Mutation and One Minimal Function Mutation and ~25 CF patients With Two Copies of the F508del Mutation in H2 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
Phase 3 data of VX-661 in patients with two Copies of the F508del mutation are expected by early 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Data from VX-661 in combination with ivacaftor in approximately 500 people with CF who have two copies of the F508del mutatioion are expected in the first half of 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Phase 3 data of VX-661 in patients with cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation, due 1H 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Data from VX-661 in combination with ivacaftor for One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function are expected in the first half of 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Tickers: VRTX, CNCE
Occurred on: Mar 06, 2017
Enrollment in VX-661 in combination with ivacaftor in people with gating mutations is expected to complete in late 2016 or early 2017
Ticker: VRTX
Occurred on: Jan 08, 2017
Vertex (VRTX) Announces Phase 3 Results Evaluating ORKAMBI in Children 6-11 with Cystic Fibrosis with Two Copies of F508del Mutation
Ticker: VRTX
Occurred on: Nov 07, 2016
Vertex (VRTX) Initiates Phase 2 Study Evaluating VX-440/Tezacaftor/Kalydeco in ~40 CF Patients With F508del Mutation and One Minimal Function Mutation and ~25 CF patients With Two Copies of the F508del Mutation
Ticker: VRTX
Occurred on: Oct 25, 2016
Vertex (VRTX) Initiates Phase 2 Study Evaluating Triple Combination Dosing With VX-152 in ~35 CF Patients With One F508del Mutation and One Minimal Function Mutation and ~25 CF Patients with Two Copies of F508del.
Ticker: VRTX
Occurred on: Oct 25, 2016
The FDA set a target review date of September 30, 2016 for a decision on Orkambi sNDA in Homozygous patients aged 6-11
Ticker: VRTX
Occurred on: Sep 28, 2016
Vertex has terminated clinical development of lead pipeline candidate VX-661, in combination with Kalydeco (ivacaftor), for the treatment of cystic fibrosis (CF) patients
Ticker: VRTX
Occurred on: Aug 15, 2016
VX-661 and ivacaftor did not result in a pre-specified improvement in lung function in people with mutations that result in minimal CFTR function; Vertex plans to close this study based on the recommendation of the DSMB
Ticker: VRTX
Occurred on: Aug 15, 2016
FDA rejects Vertex's application for expanded use of KALYDECO
Ticker: VRTX
Occurred on: Feb 05, 2016
PDUFA priority review February 6, 2016 for sNDA of ALYDECO (ivacaftor) for Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations
Ticker: VRTX
Occurred on: Feb 05, 2016

Strategic Initiatives (VRTX)

Vertex (VRTX) and Merck KgaA (MKGAY) Announce Collaboration and License Agreement Covering Four Oncology R&D Programs
Tickers: MRK, VRTX, MKGAY
Announcement Date: Jan 11, 2017
Vertex Pharmaceuticals (VRTX) Expands Agreement with Cystic Fibrosis Foundation Therapeutics (CFFT)
Ticker: VRTX
Announcement Date: Oct 14, 2016
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics for Cystic Fibrosis
Tickers: VRTX, Moderna
Announcement Date: Jul 06, 2016

VRTX Overview